Open AccessTumor Suppressors and Cell-Cycle Proteins in Lung Cancer
Author(s) -
Alfonso Baldi,
Antonio De Luca,
Vincenzo Esposito,
Mara Campioni,
Enrico P. Spugnini,
Gennaro Citro
Publication year - 2011
Publication title -
pathology research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 21
eISSN - 2090-8091
pISSN - 2042-003X
DOI - 10.4061/2011/605042
Subject(s) - cyclin dependent kinase , cell cycle , kinase , lung cancer , cancer research , microbiology and biotechnology , polo like kinase , cyclin , cell cycle progression , cell cycle protein , cell , cdk inhibitor , medicine , cancer , biology , bioinformatics , pathology , genetics
The cell cycle is the cascade of events that allows a growing cell to duplicate all its components and split into two daughter cells. Cell cycle progression is mediated by the activation of a highly conserved family of protein kinases, the cyclin-dependent kinases (CDKs). CDKs are also regulated by related proteins called cdk inhibitors grouped into two families: the INK4 inhibitors (p16, p15, p19, and p18) and the Cip/Kip inhibitors (p21, p27, and p53). Several studies report the importance of cell-cycle proteins in the pathogenesis and the prognosis of lung cancer. This paper will review the most recent data from the literature about the regulation of cell cycle. Finally, based essentially on the data generated in our laboratory, the expression, the diagnostic, and prognostic significance of cell-cycle molecules in lung cancer will be examined
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom